CELL SEARCH SYSTEM -CELL BANK- (RIKEN BRC) [RCB1292 : RBE]

21103 Shi L, Shen W, Davis MI, Kong K, Vu P, Saha SK, Adil R, Kreuzer J, Egan R, Lee TD, Greninger P, Shrimp JH, Zhao W, Wei TY, Zhou M, Eccleston J, Sussman J, Manocha U, Weerasekara V, Kondo H, Vijay V, Wu MJ, Kearney SE, Ho J, McClanaghan J, Murchie E, Crowther GS, Patnaik S, Boxer MB, Shen M, Ting DT, Kim WY, Stanger BZ, Deshpande V, Ferrone CR, Benes CH, Haas W, Hall MD, Bardeesy N. SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers. Nat Cancer 2023 PubMed ID: 36914816 DOI: 10.1038/s43018-023-00523-0

21205 Mohan A, Griffith KA, Wuchu F, Zhen DB, Kumar-Sinha C, Crysler O, Hsiehchen D, Enzler T, Dippman D, Gunchick V, Achreja A, Animasahun O, Choppara S, Nenwani M, Chinnaiyan AM, Nagrath D, Zalupski MM, Sahai V. Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04). Clin Cancer Res 2023 PubMed ID: 37115501 DOI: 10.1158/1078-0432.CCR-23-0036

21324 Liu D, Shi Y, Chen H, Nisar MA, Jabara N, Langwinski N, Mattson S, Nagaoka K, Bai X, Lu S, Huang CK. Molecular profiling reveals potential targets in cholangiocarcinoma. World J Gastroenterol 2023 29(25):4053-4071 PubMed ID: 37476584 DOI: 10.3748/wjg.v29.i25.4053

21390 Chen CP, Yeh CN, Pan YR, Huang WK, Hsiao YT, Lo CH, Wu CE. Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer. Biomed Pharmacother 2023 166:115389 PubMed ID: 37659202 DOI: 10.1016/j.biopha.2023.115389

21500 Pan YR, Lai JC, Huang WK, Peng PH, Jung SM, Lin SH, Chen CP, Wu CE, Hung TH, Yu AL, Wu KJ, Yeh CN. PLK1 and its substrate MISP facilitate intrahepatic cholangiocarcinoma progression by promoting lymphatic invasion and impairing E-cadherin adherens junctions. Cancer Gene Ther 2023 PubMed ID: 38057358 DOI: 10.1038/s41417-023-00705-z

17553 Koike K, Masuda T, Sato K, Fujii A, Wakiyama H, Tobo T, Takahashi J, Motomura Y, Nakano T, Saito H, Matsumoto Y, Otsu H, Takeishi K, Yonemura Y, Mimori K, Nakagawa T. GET4 is a novel driver gene in colorectal cancer that regulates the localization of BAG6, a nucleocytoplasmic shuttling protein Cancer Sci 2022 113(1):156-169 PubMed ID: 34704338 DOI: 10.1111/cas.15174

17715 Zhang L, Ma D, Li F, Qiu G, Sun D, Zeng Z. Lnc-PKD2-2-3/miR-328/GPAM ceRNA Network Induces Cholangiocarcinoma Proliferation, Invasion and 5-FU Chemoresistance Front Oncol 2022 12:871281 PubMed ID: 35965521 DOI: 10.3389/fonc.2022.871281

18223 Mancarella S, Serino G, Gigante I, Cigliano A, Ribback S, Sanese P, Grossi V, Simone C, Armentano R, Evert M, Calvisi DF, Giannelli G. CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype J Exp Clin Cancer Res 2022 41(1):65 PubMed ID: 35172861 DOI: 10.1186/s13046-022-02283-8

20420 Chui NN, Cheu JW, Yuen VW, Chiu DK, Goh CC, Lee D, Zhang MS, Ng IO, Wong CC. Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1. Hepatol Commun 2022 PubMed ID: 34558800 DOI: 10.1002/hep4.1682

20697 Supradit K, Boonsri B, Duangdara J, Thitiphatphuvanon T, Suriyonplengsaeng C, Kangsamaksin T, Janvilisri T, Tohtong R, Yacqub-Usman K, Grabowska AM, Bates DO, Wongprasert K. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis. Toxicol In Vitro 2022 105385 PubMed ID: 35568131 DOI: 10.1016/j.tiv.2022.105385

20723 Satow R, Aiga Y, Watanabe T, Ishizuka N, Yoneda A, Fukami K. Zic family member 5 promotes survival in human pancreatic cancer and cholangiocarcinoma cells. Biochem Biophys Rep 2022 31:101289 PubMed ID: 35669984 DOI: 10.1016/j.bbrep.2022.101289

20763 Tanaka R, Kimura K, Eguchi S, Ohira G, Tanaka S, Amano R, Tanaka H, Yashiro M, Ohira M, Kubo S. Interleukin-8 produced from cancer-associated fibroblasts suppresses proliferation of the OCUCh-LM1 cancer cell line. BMC Cancer 2022 22(1):748 PubMed ID: 35804329 DOI: 10.1186/s12885-022-09847-z

20772 Tanaka M, Kunita A, Yamagishi M, Katoh H, Ishikawa S, Yamamoto H, Abe J, Arita J, Hasegawa K, Shibata T, Ushiku T. KRAS mutation in intrahepatic cholangiocarcinoma: linkage with metastasis-free survival and reduced E-cadherin expression. Liver Int 2022 PubMed ID: 35833881 DOI: 10.1111/liv.15366

20794 Chen S, Nishi M, Morine Y, Yoshikawa K, Tokunaga T, Kashihara H, Takasu C, Wada Y, Yoshimoto T, Nakamoto A, Sakai T, Shimada M. Polymethoxylated flavone sudachitin is a safe anticancer adjuvant that targets glycolysis in cancer-associated fibroblasts. Oncol Lett 2022 24(1):236 PubMed ID: 35720469 DOI: 10.3892/ol.2022.13356

20925 Wu CE, Chen CP, Pan YR, Jung SM, Chang JW, Chen JS, Yeh CN, Lunec J. In vitro and in vivo study of GSK2830371 and RG7388 combination in liver adenocarcinoma. Am J Cancer Res 2022 12(9):4399-4410 PubMed ID: 36225643

13539 Nagaoka K, Ogawa K, Ji C, Cao KY, Bai X, Mulla J, Cheng Z, Wands JR, Huang CK. Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis Dig Dis Sci 2021 66(4):1080-1089 PubMed ID: 32445050 DOI: 10.1007/s10620-020-06330-2

15516 Hozaka Y, Seki N, Tanaka T, Asai S, Moriya S, Idichi T, Wada M, Tanoue K, Kawasaki Y, Mataki Y, Kurahara H, Ohtsuka T. Molecular Pathogenesis and Regulation of the miR-29-3p-Family: Involvement of ITGA6 and ITGB1 in Intra-Hepatic Cholangiocarcinoma ancers (Basel) 2021 13(11):2804 PubMed ID: 34199886 DOI: 10.3390/cancers13112804

16118 Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Yan I, Aso K, Fujii S, Patel T, Haneda M Extracellular RNA transfer from non-malignant human cholangiocytes can promote cholangiocarcinoma growth FEBS Open Bio 2021 11(12):3276-329 PubMed ID: 34510808 DOI: 10.1002/2211-5463.13294

12038 Yamanaka T, Harimoto N, Yokobori T, Muranushi R, Hoshino K, Hagiwara K, Gantumur D, Handa T, Ishii N, Tsukagoshi M, Igarashi T, Tanaka H, Watanabe A, Kubo N, Araki K, Shirabe K. Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts. Br. J. Cancer 2020 PubMed ID: 32015511 DOI: 10.1038/s41416-020-0744-7

12462 Yoshino J, Akiyama Y, Shimada S, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Yamaoka S, Tanabe M, Tanaka S. Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma Carcinogenesis 2020 41(6):734-742 PubMed ID: 31665232 DOI: 10.1093/carcin/bgz179

13005 Hsieh CH, Chu CY, Lin SE, Yang YSH, Chang HS, Yen Y. TESC Promotes TGF-α/EGFR-FOXM1-Mediated Tumor Progression in Cholangiocarcinoma. Cancers (Basel) 2020 PubMed ID: 32365487 DOI: 10.3390/cancers12051105

13336 Pan YR, Wu CE, Yeh CN. ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner. Biomolecules 2020 PubMed ID: 33182492 DOI: 10.3390/biom10111529

13579 Arora M, Bogenberger JM, Abdelrahman A, Leiting JL, Chen X, Egan JB, Kasimsetty A, Lenkiewicz E, Malasi S, Uson PLS, Nagalo BM, Zhou Y, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Truty MJ, Borad MJ. Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer Cancer Chemother Pharmacol 2020 85(6):1063-1078 PubMed ID: 32440762 DOI: 10.1007/s00280-020-04079-z

13917 Tamai K, Nakamura-Shima M, Shibuya-Takahashi R, Kanno SI, Yasui A, Mochizuki M, Iwai W, Wakui Y, Abue M, Yamamoto K, Miura K, Mizuma M, Unno M, Kawamura S, Sato I, Yasuda J, Yamaguchi K, BEX2 suppresses mitochondrial activity and is required for dormant cancer stem cell maintenance in intrahepatic cholangiocarcinoma Sci Rep 2020 10(1):21592 PubMed ID: 33299012 DOI: 10.1038/s41598-020-78539-0

16133 Fu W, Yu G, Liang J, Fan P, Dong K, Zhang B, Chen X, Zhu H, Chu L. miR-144-5p and miR-451a Inhibit the Growth of Cholangiocarcinoma Cells Through Decreasing the Expression of ST8SIA4 Front Oncol 2020 10:563486 PubMed ID: 33520692 DOI: 10.3389/fonc.2020.563486

11443 Brun S, Bassissi F, Serdjebi C, Novello M, Tracz J, Autelitano F, Guillemot M, Fabre P, Courcambeck J, Ansaldi C, Raymond E, Halfon P. GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma. Invest New Drugs 2019 PubMed ID: 30778887 DOI: 10.1007/s10637-019-00741-3

14816 Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma Cancer Discov 2019 9(8):1064-1079 PubMed ID: 31109923 DOI: 10.1158/2159-8290.CD-19-0182

10658 Yokoi K, Kobayashi A, Motoyama H, Kitazawa M, Shimizu A, Notake T, Yokoyama T, Matsumura T, Takeoka M, Miyagawa SI. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. Oncol. Rep. 2018 39:843-850 PubMed ID: 29251327 DOI: 10.3892/or.2017.6153

10816 Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Aso K, Makino Y, Fujii S, Ota T, Haneda M. Extracellular vesicle-encapsulated miR-30e suppresses cholangiocarcinoma cell invasion and migration via inhibiting epithelial-mesenchymal transition. Oncotarget 2018 9:16400-16417 PubMed ID: 29662654 DOI: 10.18632/oncotarget.24711

11206 Yamaoka R, Ishii T, Kawai T, Yasuchika K, Miyauchi Y, Kojima H, Katayama H, Ogiso S, Fukumitsu K, Uemoto S. CD90 expression in human intrahepatic cholangiocarcinoma is associated with lymph node metastasis and poor prognosis. J Surg Oncol 2018 PubMed ID: 30196535 DOI: 10.1002/jso.25192

4337 Nakagawa S, Okabe H, Ouchi M, Tokunaga R, Umezaki N, Higashi T, Kaida T, Arima K, Kitano Y, Kuroki H, Mima K, Nitta H, Imai K, Hashimoto D, Yamashita YI, Chikamoto A, Baba H. Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma. HPB (Oxford) 2018 PubMed ID: 29759640 DOI: 10.1016/j.hpb.2018.03.018

4338 Fujiwara H, Tateishi K, Kato H, Nakatsuka T, Yamamoto K, Tanaka Y, Ijichi H, Takahara N, Mizuno S, Kogure H, Matsubara S, Nakai Y, Koike K. Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1. Cancer Sci. 2018 PubMed ID: 30156013 DOI: 10.1111/cas.13784

4339 Mori A, Masuda K, Ohtsuka H, Shijo M, Ariake K, Fukase K, Sakata N, Mizuma M, Morikawa T, Hayashi H, Nakagawa K, Motoi F, Naitoh T, Fujishima F, Unno M. FBXW7 modulates malignant potential and cisplatin-induced apoptosis in cholangiocarcinoma through NOTCH1 and MCL1. Cancer Sci. 2018 PubMed ID: 30302867 DOI: 10.1111/cas.13829

4486 Nepal C, O'Rourke CJ, Oliveira DVNP, Taranta A, Shema S, Gautam P, Calderaro J, Barbour A, Raggi C, Wennerberg K, Wang XW, Lautem A, Roberts LR, Andersen JB. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology 2018 68(3):949-963 PubMed ID: 29278425 DOI: 10.1002/hep.29764

5802 Eguchi T et al Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment. PLoS One 2018 13(2):e0191109. PubMed ID: 29415026 DOI: 10.1371/journal.pone.0191109

14913 Lin G, Lin KJ, Wang F, Chen TC, Yen TC, Yeh TS. Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity Dis Model Mech 2018 11(8):dmm03305 PubMed ID: 29666220 DOI: 10.1242/dmm.033050

14942 Wang J, Dong M, Xu Z, Song X, Zhang S, Qiao Y, Che L, Gordan J, Hu K, Liu Y, Calvisi DF, Chen X. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice Oncogene 2018 ;37(24):3229-3242 PubMed ID: 29545603 DOI: 10.1038/s41388-018-0188-1

10290 Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS. High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy. Mol. Carcinog. 2017 56:2146-2157 PubMed ID: 28467612 DOI: 10.1002/mc.22671

10333 Huang G-, Liu TT, Weng SW, You HL, Wei YC, Chen CH, Eng HL, Huang WT. CUL4A overexpression as an independent adverse prognosticator in intrahepatic cholangiocarcinoma. BMC Cancer 2017 17:395 PubMed ID: 28576144 DOI: 10.1186/s12885-017-3389-z

10501 Kushibiki T, Noji T, Ebihara Y, Hontani K, Ono M, Kuwabara S, Nakamura T, Tsuchikawa T, Okamura K, Ishizuka M, Hirano S. 5-Aminolevulinic-acid-mediated Photodynamic Diagnosis Enhances the Detection of Peritoneal Metastases in Biliary Tract Cancer in Mice. In Vivo 2017 31:905-908 PubMed ID: 28882957 DOI: 10.21873/invivo.11145

14252 Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S. Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification Int J Oncol 2017 50(1):129-140. PubMed ID: 27922671 DOI: 10.3892/ijo.2016.3786

14528 Yagai T, Matsui S, Harada K, Inagaki FF, Saijou E, Miura Y, Nakanuma Y, Miyajima A, Tanaka M. Expression and localization of sterile alpha motif domain containing 5 is associated with cell type and malignancy of biliary tree PLoS One 2017 12(4):e0175355 PubMed ID: 28388653 DOI: 10.1371/journal.pone.0175355

9923 Aoki S, Mizuma M, Takahashi Y, Haji Y, Okada R, Abe T, Karasawa H, Tamai K, Okada T, Morikawa T, Hayashi H, Nakagawa K, Motoi F, Naitoh T, Katayose Y, Unno M. Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: clinicopathological features and therapeutic potential for cancer stem cell-like properties. BMC Cancer 2016 16:854 PubMed ID: 27821106 DOI: 10.1186/s12885-016-2919-4

3735 Saha SK et al Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discov 2016 6(7):727-39 PubMed ID: 27231123 DOI: 10.1158/2159-8290.CD-15-1442

12878 Yang SH, Lin HY, Changou CA, Chen CH, Liu YR, Wang J, Jiang X, Luh F, Yen Y. Integrin β3 and LKB1 are independently involved in the inhibition of proliferation by lovastatin in human intrahepatic cholangiocarcinoma Oncotarget 2016 7(1):362-73 PubMed ID: 26517522 DOI: 10.18632/oncotarget.6238

5025 Sakamoto K, Imai K, Higashi T, Taki K, Nakagawa S, Okabe H, Nitta H, Hayashi H, Chikamoto A, Ishiko T, Beppu T, Baba H. Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer. Cancer Sci 2015 106(9):1153-62 PubMed ID: 26132727 DOI: 10.1111/cas.12732

15203 Wang J, Zhang K, Wang J, Wu X, Liu X, Li B, Zhu Y, Yu Y, Cheng Q, Hu Z, Guo C, Hu S, Mu B, Tsai CH, Li J, Smith L, Yang L, Liu Q, Chu P, Chang V, Zhang B, Wu M, Jiang X, Yen Y. Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma Oncotarget 2015 6(22):18905-20 PubMed ID: 26056085 DOI: 10.18632/oncotarget.4305

14098 Liu TT, You HL, Weng SW, Wei YC, Eng HL, Huang WT. Recurrent Amplification at 13q34 Targets at CUL4A, IRS2, and TFDP1 As an Independent Adverse Prognosticator in Intrahepatic Cholangiocarcinoma PLoS One 2015 10(12):e0145388 PubMed ID: 26684807 DOI: 10.1371/journal.pone.0145388

12541 Soejima Y, Inoue M, Takahashi Y, Uozaki H, Sawabe M, Fukusato T. ntegrins αvβ6, α6β4 and α3β1 are down-regulated in cholangiolocellular carcinoma but not cholangiocarcinoma Hepatol Res 2014 44(14):E320-34 PubMed ID: 24552196 DOI: 10.1111/hepr.12312

14393 Nakagawa S, Sakamoto Y, Okabe H, Hayashi H, Hashimoto D, Yokoyama N, Tokunaga R, Sakamoto K, Kuroki H, Mima K, Beppu T, Baba H. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells Oncol Rep 2014 31(2):983-8 PubMed ID: 24337160 DOI: 10.3892/or.2013.2922

16018 Jachin S, Bae JS, Sung JJ, Park HS, Jang KY, Chung MJ, Kim DG, Moon WS. The role of nuclear EpICD in extrahepatic cholangiocarcinoma: association with β-catenin Int J Oncol 2014 45(2):691-8 PubMed ID: 24888903 DOI: 10.3892/ijo.2014.2472

18681 Lange S, Lampe J, Bossow S, Zimmermann M, Neubert W, Bitzer M, Lauer UM. A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma Hum Gene Ther 2013 24(5):554-64 PubMed ID: 23550539 DOI: 10.1089/hum.2012.136

12544 Kumagai A, Fukushima J, Takikawa H, Fukuda T, Fukusato T. Enhanced expression of farnesoid X receptor in human hepatocellular carcinoma Hepatol Res 2013 43(9):959-69 PubMed ID: 23369163 DOI: 10.1111/hepr.12047

16575 Jamiyandorj U, Bae JS, Noh SJ, Jachin S, Choi JE, Jang KY, Chung MJ, Kang MJ, Lee DG, Moon WS. Expression of peptidyl-prolyl isomerase PIN1 and its role in the pathogenesis of extrahepatic cholangiocarcinoma Oncol Lett 2013 6(5):1421-1426 PubMed ID: 24179535 DOI: 10.3892/ol.2013.1525

17161 Lin Y, Zhang B, Liang H, Lu Y, Ai X, Zhang B, Chen X. JNK inhibitor SP600125 enhances TGF-β-induced apoptosis of RBE human cholangiocarcinoma cells in a Smad-dependent manner Mol Med Rep 2013 8(6):1623-9 PubMed ID: 24100678 DOI: 10.3892/mmr.2013.1711

5863 Yoshii Y, Waki A, Yoshida K, Kakezuka A, Kobayashi M, Namiki H, Kuroda Y, Kiyono Y, Yoshii H, Furukawa T, Asai T, Okazawa H, Gelovani JG, Fujibayashi Y. The use of nanoimprinted scaffolds as 3D culture models to facilitate spontaneous tumor cell migration and well-regulated spheroid formation. Biomaterials 2011 32(26):6052-8 PubMed ID: 21640378 DOI: 10.1016/j.biomaterials.2011.04.076

8365 Ishii T, Yasuchika K, Suemori H, Nakatsuji N, Ikai I, Uemoto S. Alpha-fetoprotein producing cells act as cancer progenitor cells in human cholangiocarcinoma. Cancer Lett. 2010 294:25-34 PubMed ID: 20149523 DOI: 10.1016/j.canlet.2010.01.019

6410 Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y. Is parainfluenza virus a threatening virus for human cancer cell lines? Hum Cell 2009 22(3):81-4 PubMed ID: 19624309 DOI: 10.1111/j.1749-0774.2009.00071.x

12770 Xu HL, Inagaki Y, Seyama Y, Sugawara Y, Kokudo N, Nakata M, Wang FS, Tang W. Expression of KL-6 mucin, a human MUC1 mucin, in intrahepatic cholangiocarcinoma and its potential involvement in tumor cell adhesion and invasion Life Sci 2009 85(9-10):395-400 PubMed ID: 19631667 DOI: 10.1016/j.lfs.2009.07.004

18314 Tanaka Y, Kanai F, Tada M, Tateishi R, Sanada M, Nannya Y, Ohta M, Asaoka Y, Seto M, Shiina S, Yoshida H, Kawabe T, Yokosuka O, Ogawa S, Omata M. Gain of GRHL2 is associated with early recurrence of hepatocellular carcinoma J Hepatol 2008 49(5):746-57. PubMed ID: 18752864 DOI: 10.1016/j.jhep.2008.06.019

18693 Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, Hirohashi S. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer Gastroenterology 2008 135(4):1358-1368 PubMed ID: 18692501 DOI: 10.1053/j.gastro.2008.06.082

3575 Komori J, Marusawa H, Machimoto T, Endo Y, Kinoshita K, Kou T, Haga H, Ikai I, Uemoto S, Chiba T. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 2008 47(3):888-96 PubMed ID: 18306229 DOI: 10.1002/hep.22125

3077 Nakatsu N, Yoshida Y, Yamazaki K, Nakamura T, Dan S, Fukui Y, Yamori T Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Mol Cancer Ther 2005 4:399-412 PubMed ID: 15767549 DOI: 10.1158/1535-7163.MCT-04-0234

3334 Obama, Kazutaka, Ura, Katsuaki, Satoh, Seiji, Nakamura, Yusuke, Furukawa, Yoichi Up-regulation of PSF2, a member of the GINS multiprotein complex, in intrahepatic cholangiocarcinoma Oncol Res 2005 14:701-706 PubMed ID: 16077978

3346 Yokoo, Hideki, Kondo, Tadashi, Fujii, Kazuyasu, Yamada, Tesshi, Todo, Satoru, Hirohashi, Setsuo Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology 2004 40:609-17 PubMed ID: 15349899 DOI: 10.1002/hep.20372

3703 Sanada T, Yokoi S, Arii S, Yasui K, Imoto I, Inazawa J. Skp2 overexpression is a p27Kip1-independent predictor of poor prognosis in patients with biliary tract cancers. Cancer Sci 2004 95(12):969-76 PubMed ID: 15596046 DOI: 10.1111/j.1349-7006.2004.tb03185.x